A Phase I/II Dose-Escalation Trial of Leflunomide in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Trial Profile

A Phase I/II Dose-Escalation Trial of Leflunomide in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Leflunomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Dec 2016 Planned number of patients changed from 42 to 39.
    • 04 Nov 2015 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2017 as reported by ClinicalTrials.gov record.
    • 04 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top